Commentary: Adjuvant Oral Antibiotics for Infective Endocarditis: Overkill or Warranted?

Semin Thorac Cardiovasc Surg. 2021 Autumn;33(3):701-702. doi: 10.1053/j.semtcvs.2020.10.005. Epub 2020 Nov 7.

Authors

Sameer Hirji¹, Paige Newell¹, Tsuyoshi Kaneko²

Affiliations

¹ Division of Cardiac Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
² Division of Cardiac Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: tkaneko2@bwh.harvard.edu.

PMID: 33171250
DOI: 10.1053/j.semtcvs.2020.10.005

No abstract available

Publication types

Editorial
Comment

MeSH terms

Anti-Bacterial Agents / adverse effects
Endocarditis* / diagnosis
Endocarditis* / drug therapy
Endocarditis, Bacterial* / diagnosis
Endocarditis, Bacterial* / drug therapy
Humans

Substances

Anti-Bacterial Agents